Ingelvac CircoFLEX® Gains Additional EMA Approval

European Medicines Agency (EMA) approves the use of Ingelvac CircoFLEX® during pregnancy and lactation in sows

  • Ingelvac CircoFLEX® is registered worldwide to protect pigs against Porcine Circovirus Type 2 (PCV2) associated diseases and is the market leading piglet vaccine in this product segment.1
  • The vaccine has now additionally been approved by the European Medicines Agency (EMA) for the use in pregnant and lactating sows against PCV2.
  • PCV2 can cause a variety of clinical signs in pigs, such as wasting and reproductive disease, but also subclinical infections.

Ingelheim, Germany, 07 September 2015 – The European Medicines Agency (EMA) has granted the use of Boehringer Ingelheim’s Ingelvac CircoFLEX® during pregnancy and lactation in sows. The vaccine is registered worldwide for the protection of pigs against Porcine Circovirus Type 2 (PCV2) related diseases. Ingelvac CircoFLEX® reduces mortality, clinical signs and lesions associated with PCV2.

Today, piglet vaccination is the global standard measure for the prevention of PCV2 related diseases in pigs; Ingelvac CircoFLEX® is the global market leader in this product segment.1

George Heidgerken, Head of Boehringer Ingelheim ​Animal Health
George Heidgerken, Head
of Boehringer Ingelheim
Animal Health

George Heidgerken, Head of Boehringer Ingelheim Animal Health said: “Ingelvac CircoFLEX® is the first PCV2 vaccine licensed in the European Union to protect piglets as well as sows. We are proud that we can now offer veterinarians and farmers the means for an even broader protection of pig herds against this fatal virus.”

PCV2 can have a devastating impact on the pigs’ health, causing suffering to the animals and economic damage to the farmers. An infection with this virus may lead to wasting, paleness of the skin, dyspnea or diarrhea in piglets. In breeding herds, PCV2 infection can cause reproductive losses in sows. In both, piglets and sows, PCV2 can also cause medically and economically relevant subclinical infections (infections without evident clinical signs).
It has been demonstrated in further studies that sow vaccination with Ingelvac CircoFLEX® has significant positive effects on the reproductive performance, in particular the farrowing rate, the number of piglets born alive and weaned per litter.2,3,4,5,6

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

For more information please visit www.boehringer-ingelheim.com

Referências

  1. Based on local and international market research data (data on file).
  2. Misener M. et al. 2014: Impact of Reproductive Performance on a sow herd vaccinated with Ingelvac CircoFLEX®. Proceedings of the 2014 Allen D. Leman Swine Conference, p. 39.
  3. Hauray K. and Delisle G. 2013: Effect of mass vaccination of Ingelvac CircoFLEX® on reproductive performance of sows. Proceedings of the European Symposium of Porcine Health Management 2013, p. 113.
  4. Menard J. 2011: Vaccinating sows and gilts for PCV2 in PRRS positive herds – a case report. Proceedings of the 2011 ISERPD - International Symposium on Emerging and Reemerging Pig Diseases, p. 241.
  5. Grimbeek P. J. 2010: The reproduction and production improvements in a South African commercial piggery after introducing whole herd vaccination against PCV2. Proceedings of the 21st International Pig Veterinary Society Congress, p. 372.
  6. Kostuchenko E. et al. 2013: Positive Impact of PCV2 vaccination of gilts and sows on reproductive performance demonstrated in a side by side field observation. Proceedings of the 2013 Allen D. Leman Swine Conference, p. 204.